TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02260414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
Study: NCT03321292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine 1000 mg and Acetylesalicylic acid75mg
Description: l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid 75 mg
Description: acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
Study: NCT01254396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Orally Disintegrating Tablet, 50 mg, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Orally Disintegrating Tablet, 50 mg, Single Dose
Study: NCT02133378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Baxter Hemopatch

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Traditional Hemostasis Techniques (dry or wet gauze compression or similar)
Study: NCT04227977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JuxtaFlow System
Description: The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
Study: NCT00807547

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergy vaccination (Alutard SQ)
Description: Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allergy vaccination (Alutard SQ)
Description: Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
Study: NCT00923910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WT1 Peptide-Pulsed Dendritic Cells

Intervention type: DRUG
Group type: OTHER
Intervention: Donor Lymphocytes
Description: Lymphocytes from donors (related or unrelated) collected via lymphapheresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor Lymphocytes
Description: Lymphocytes from donors (related or unrelated) collected via lymphapheresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-4
Description: water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
Study: NCT03021876

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual intake
Description: baseliner
Study: NCT00004162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT03401879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA)
Description: Retinal microvasculature will be assessed using OCTA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA)
Description: Retinal microvasculature will be assessed using OCTA.
Study: NCT00004162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study: NCT03591965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-008
Description: Approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg/QD and another 20 subjects will receive oral ATG-008 at an initial dose of 20mg/BID for 28 days each cycle.
Study: NCT00004162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT03985124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids for Teachers
Description: This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
Study: NCT02115776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate
Description: Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate
Description: Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
Study: NCT03166527

Intervention type: DRUG
Group type: OTHER
Intervention: Immune Globulin 10% Intravenous Solution
Description: standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
Study: NCT01152112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myomectomy
Description: Removal of fibroids and / or polyps

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myomectomy
Description: Removal of fibroids and / or polyps
Study: NCT02156453

Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: All patients will undergo total knee replacement using midvastus approach by single surgeon.
Study: NCT00111696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
Study: NCT01299779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-SD
Description: PEG-SD~* Bisacodyl: two 5-mg tablets at 3 pm day prior~* 1L sports drink\* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~* 1L SD\* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~  * Same flavor, non-red Gatorade® for all patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS
Description: * 1L + 500 cc clear liquids at 6 pm night prior~* 1L + 500 cc clear liquids starting 4 hours prior to colonoscopy
Study: NCT04485806

Intervention type: OTHER
Group type: OTHER
Intervention: GPS/LM
Description: Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay

Intervention type: OTHER
Group type: OTHER
Intervention: GPS/LM
Description: Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay

Intervention type: OTHER
Group type: OTHER
Intervention: SPL/LM
Description: Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay

Intervention type: OTHER
Group type: OTHER
Intervention: SPL/LM
Description: Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay

Intervention type: OTHER
Group type: OTHER
Intervention: GPS/PO
Description: Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay

Intervention type: OTHER
Group type: OTHER
Intervention: GPS/PO
Description: Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay

Intervention type: OTHER
Group type: OTHER
Intervention: SPL/PO
Description: Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
Study: NCT02775903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
Study: NCT04485806

Intervention type: OTHER
Group type: OTHER
Intervention: SPL/PO
Description: Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
Study: NCT01994915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
Study: NCT00923910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH
Description: Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
Study: NCT01196949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manipulative and Rehabilitative Therapy
Description: Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative Therapy
Description: Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
Study: NCT03332264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent Please OTW
Description: Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eluvia Vascular Stent System
Description: Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
Study: NCT02775903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
Study: NCT01569763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Endometrial Ablation
Description: Endometrial Ablation using the Aurora Endometrial Ablation system
Study: NCT00923910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WT1 Peptides
Description: dendritic cell vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Purified lipopolysaccharide prepared from E.Coli 0:113
Study: NCT01569763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rollerball Ablation/Resection
Description: Hysteroscopic rollerball resection/ablation
Study: NCT01993784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Study: NCT03316534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (100 mg once a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin (100 mg once a day)
Study: NCT02009449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months
Study: NCT00923910

Intervention type: DRUG
Group type: OTHER
Intervention: Diphenhydramine
Description: Pre-medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Pre-medication

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Pre-medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Pre-medication
Study: NCT02009449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months
Study: NCT02354391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate Picato® and MAL PDT day 1, day 5
Description: Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate Picato® day 2, 3, 4
Description: Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
Study: NCT03332264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol stent
Description: Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent
Study: NCT02354391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAL PDT day 5
Description: Methyl aminolevulate combined with Photodynamic therapy at day 5
Study: NCT02991820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller
Description: Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller
Description: Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh
Description: Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
Study: NCT02828631

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pentax videolaryngoscope
Study: NCT00794794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine (Clarinex)
Description: Each subject received 5 mL of desloratadine syrup one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Each subject received 5 mL of cetirizine syrup
Study: NCT01073631

Intervention type: DRUG
Intervention: voriconazole tablet
Description: 200 mg PO bid (orally, twice a day)
Study: NCT03183622

Intervention type: BIOLOGICAL
Intervention: ALLO-ASC-DFU
Description: ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells
Study: NCT03354780

Intervention type: OTHER
Intervention: Survey on first pregnancy after endometriosis diagnosis
Description: rate of miscarriage was noted

Intervention type: OTHER
Intervention: Survey on first pregnancy
Description: rate of miscarriage was noted
Study: NCT01158313

Intervention type: DIETARY_SUPPLEMENT
Intervention: Thickened supplement
Description: New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
Study: NCT01389713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomifene Citrate
Description: 3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH analog and recombinant human FSH
Description: daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
Study: NCT03016806

Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation 1200 cGy
Description: Total Body Irradiation 1200 cGy in 8 fractions
Study: NCT02009449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Daily subcutaneous injections of pegilodecakin up to 12 months
Study: NCT02991820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh
Description: Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC
Description: Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC
Description: Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope
Study: NCT04947566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of Efficacy of Naproxen versus Ibuprofen
Description: Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of Efficacy of Naproxen versus Ibuprofen
Description: Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis